论文部分内容阅读
目的探讨DNA损伤修复基因核苷酸切除修复交叉互补基因2(ERCC2/XPD)和X线修复交叉互补基因1(XRCC1)的基因多态性评估食管癌预后的价值。方法采集100例食管癌患者(试验组)和80例正常受试者(对照组)静脉血,采用聚合酶链反应-限制性片段长度多态性方法检测ERCC2/XPD Lys751Gln和XRCC1Arg399Gln基因多态性,Logistic回归分析计算风险比,分析基因型与食管癌复发、转移的相关性。结果试验组和对照组变异型等位基因ERCC2/XPD Lys751Gln频率为15.7%和13.0%;与野生型Lys/Lys相比,携带Lys/Gln和Gln/Gln基因型易患食管癌(P<0.05)。试验组和对照组变异型等位基因XRCC1 399Gln频率分别为29.8%和30.2%;与野生型Arg/Arg相比,携带Arg/Gln和Gln/Gln基因型易患食管癌(P<0.05)。食管癌复发、转移与ERCC2/XPD基因Lys/Gln、Gln/Gln基因型及XRCC1 399Arg/Arg基因型相关(P<0.05),而与ERCC2/XPD Lys/Lys基因型及XRCC1 399基因Arg/Gln、Gln/Gln基因型无明显相关性(P>0.05)。结论 ERCC2/XPD和XRCC1基因多态性可增加食管癌发生风险,影响食管癌患者的预后。
Objective To investigate the value of DNA damage repair gene nucleotide excision repair cross-complementing gene 2 (ERCC2 / XPD) and X-ray repair cross-complementing gene 1 (XRCC1) gene polymorphism in the prognosis of esophageal cancer. Methods 100 cases of esophageal cancer patients (experimental group) and 80 normal subjects (control group) venous blood were collected and the polymorphisms of ERCC2 / XPD Lys751Gln and XRCC1Arg399Gln were detected by polymerase chain reaction - restriction fragment length polymorphism Logistic regression analysis was used to calculate risk ratio, and the correlation between genotypes and recurrence and metastasis of esophageal cancer was analyzed. Results The frequency of ERCC2 / XPD Lys751Gln was 15.7% and 13.0%, respectively. The Lys / Gln and Gln / Gln genotypes were more susceptible to esophageal cancer than the wild type Lys / Lys (P <0.05 ). The frequency of XRCC1 399Gln was 29.8% and 30.2% respectively in experimental group and control group. Compared with wild-type Arg / Arg, the genotypes of Arg / Gln and Gln / Gln were more susceptible to esophageal cancer (P <0.05). The recurrence and metastasis of esophageal carcinoma were correlated with the Lys / Gln, Gln / Gln genotypes and XRCC1 399Arg / Arg genotypes of ERCC2 / XPD (P <0.05), but not with ERCC2 / XPD Lys / Lys genotypes and XRCC1 399 Arg / Gln , Gln / Gln genotype no significant correlation (P> 0.05). Conclusion The polymorphisms of ERCC2 / XPD and XRCC1 may increase the risk of esophageal cancer and affect the prognosis of patients with esophageal cancer.